Strategic Partnerships Celerity Biosciences operates a specialized bio specimen service with access to an extensive bank of retrospective and prospective samples, integrated with lab services. This presents cross-sell opportunities to larger biobanking, CROs, and pharmaceutical groups seeking robust sample access and pathology support.

Integrated Lab Capabilities With ISO 15189 accredited facilities and a broad menu of immunohistochemistry, molecular pathology, digital image analysis, and sequencing panels from Illumina and Thermo Fisher, there is potential to bundle end-to-end pathology and molecular testing for CROs and biotech startups needing turnkey workflows.

Technology Enablement Existing tech stack includes digital image analysis, cloud infrastructure, and standard web tools; this can be leveraged to offer scalable, remote reporting and data delivery for customers requiring rapid turnaround and secure data sharing across global teams.

Market Positioning As a smaller player with a focused service portfolio and strategic alliances in bio specimen provisioning, Celerity can target niche contracts within larger CROs and academic centers that need flexible, rapid-access pathology and specimen services without the overhead of larger labs.

Growth Enablers Revenue is currently under one million, signaling an opportunity to pursue channel partnerships, contract manufacturing-style engagements, and expansion into additional panels or services to scale revenue with existing sequencing and IHC capabilities.